A TAU team led by Prof. Motti Gerlic and Prof. Ariel Munitz, both of TAU's Sackler Faculty of Medicine of Tel Aviv University, have developed a new test to add to the current diagnostic arsenal used to detect coronavirus infection. The unique test is serological — a blood test — and measures the presence of three type of antibodies against the virus.
RAMOT@TAU is collaborating with the Israel Defense Forces (IDF) to test thousands of soldiers using this test. In addition, a collaboration agreement was signed with Biological Industries Israel Beit Haemek on this assay.Read More
Neovii, the Swiss-based biopharmaceutical company and a member of Israeli-based Neopharm Group, has signed a research and license agreement with Tel Aviv University's (TAU) RAMOT, its technology transfer company, to work in collaboration with a team led by Professor Jonathan Gershoni of the School of Molecular Cell Biology and Biotechnology to develop a novel and potentially life-saving COVID-19 vaccine.Read More
The patent covers a vaccine that targets the most vulnerable point in a coronavirus’s structure, through which it penetrates human cells. The patent has been submitted by Ramot, the technology transfer company of Tel-Aviv University and was granted in March by the U.S. patent and trademark office.Read More
Under the terms of the Research Agreement, InnoCan and a team led by Prof. Daniel Offen, a leading researcher specializing in Neuroscience and Exosome technology at Tel Aviv University, will collaborate to develop the cell therapy product, based on Prof. Offen's work in the field. Innocan has agreed to fund the research based on agreed milestones, in the aggregate amount of approximately US $450,000 for the first stage.Read More
RAMOT@TAU Calls on Industry to Partner in Developing Novel Technologies and Research Solutions for COVID-19.
Join the global efforts to fight COVID-19!Read More
Epeius pharma develops next generation biological vehicles for delivery of therapeutic proteins into the central nervous system (CNS)Read More
Can you imagine what 2030 will look like? We can.
Tel Aviv University has been ranked 66th, and first in Israel, for the number of patents it registered in the United States during 2018, according to a ranking of 100 worldwide universities made by the National Academy of Inventors and the Intellectual Property Owners Association (IPO).Read More
Tel Aviv, May 16, 2019 – MultiVu, developing proprietary 3D imaging solutions using a single sensor and deep learning derived algorithms, today announced the completion of a $7M seed round led by Israel’s most active venture investor OurCrowd, Cardumen Capital and Hong Kong based investment firm Junson Capital.Read More
Tel Aviv, Israel, May 5, 2019, Ramot at Tel Aviv University Ltd announced that its Board of Directors has appointed Keren Primor Cohen as Ramot’s new CEO, to be effective from June 2nd, 2019. Keren previously held the position of VP General Counsel and Business Affairs at Ramot.Read More
QART (Quantitative Assisted Reproductive Technologies) Medical, is a clinical-stage MedTech company, addressing the global infertility epidemic.
Tel Aviv, Israel, March 19, 2019, Tel Aviv University (TAU), Technology Innovation Momentum Fund, managed by Ramot, TAU’s Business Engagement Center and Chartered Investment Managers, a SEA-based investment management fund announced the completion of an investment round in QART Medical.Read More
Phylogica has entered into a Research and Development Collaboration with Ramot, the Business Engagement Center at Tel Aviv University to further develop the research of Professor Dan Peer of Tel Aviv University in Israel.Read More
Tel Aviv, Israel, March 6, 2019, Tel Aviv University (TAU), Technology Innovation Momentum Fund, managed by Ramot, TAU’s Business Engagement Center has entered into a license agreement with Trobix Bio, a newly formed start-up company, to develop and commercialize its antimicrobial resistance platform technology. Following the license agreement, Trobix Bio has completed its initial funding round, led by Chartered Opus investment group.Read More
Ramot and BioNTech RNA Pharmaceuticals GmbH, a leader in the development of precise and individualized immunotherapies with a broad and rapidly growing clinical pipeline today announced, that they have entered into a license agreement to further explore a set of novel lipids for improved mRNA delivery in various therapeutic indications.
Protein snippet normalizes disrupted neural connectivity caused by genetic disorder, Tel Aviv University researchers sayRead More
TEL AVIV, ISRAEL, October 8th, Tel Aviv University (TAU) through Ramot, its Business Engagement Center, announce the signing of a collaboration agreement with Novartis to explore several applications and uses of a novel platform for identified new targets and modulators of the ubiquitin pathways developed by Prof. Gali Prag from the TAU School of Neurobiology Biochemistry and Biophysics.Read More
Bsense Bio Therapeutics is our new spin-off for the treatment of neuropathic pain.Read More
Satisfaction survey results, call for proposals, new videos and startups updates...Read More
New Joint Venture NEMIS Technologies, Formed by Biosynth and Ramot at Tel Aviv University Develops Rapid Diagnostic Tests for Pathogenic Bacteria in Food Safety and Clinical ApplicationsRead More
Bridging between industry and TAU researchers is one of the primary areas in which Ramot strives to succeed.
Last February we engaged with a third-party industry expert (https://www.metrics-institute.net/) to conduct an anonymous satisfaction survey with two critical populations: our researchers and our industry partners.Read More
All amazing things come in ONE!
A low cost & simple camera design which senses color & depth information from one optical system in one exposure... by Prof. David Mendlovic - Tel Aviv University
Come see us at MWC in Barcelona and contact Mr. Oren Calfon, VP Business Development, Ramot - Tel Aviv University - email@example.comRead More
Only last August, Ramot at Tel Aviv University and BIOSYNTH AG announced their joint development work on novel detection molecules. The subject of this cooperation is the AquaSpark™ technology for chemiluminescence-based markers. They represent state-of-the-art technology and considerably improve the detection limits of diagnostic tests in comparison to existing conventional systems.Read More
Selected proposals will be funded with amounts of $40,000-$100,000 per annum, for a two-year period, beginning December 15, 2018.
The Annual Joy grant initiative aims to promote and contribute to the emerging field of neuro- wellness.Read More
As the sun rises on the new year, it's a great opportunity to set ambitious goals and think of how to make the most of funding from Ramot’s Value Enhancement programs. Read on to see how you too can transform your promising innovations from ideas to commercialization.Read More
Recently, pharmaceutical firm Baxter International and Tel Aviv University's tech transfer office Ramot announced joint research initiatives for...Read More
... its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.Read More
Ramot of Tel Aviv University, which counts Tata Industries as a partner, has developed a technology that can potentially reverse antibiotic resistanceRead More
"Chemiluminescence, the process that lights up glow sticks, occurs when a chemical reaction produces light. Researchers from Tel Aviv University developed new reagents to visually detect molecular processes inside cells or biological samples."Read More
Wipro and Ramot, the Business Engagement Center at Tel Aviv University announced a partnership for joint research in emerging technologies. The partnership envisages the creation of joint research capability at TAU, supported by Wipro to pursue core as well as applied research in fast-developing technologies in the Artificial Intelligence spaceRead More
“Innovative Companies Get Their Best Ideas from Academic Research” Harvard Business Review / Greg Satell, April 2016.Read More
Tel Aviv, Israel, January 25, 2017 - Ramot, the business engagement company of Tel Aviv University, today announced a sponsored research collaboration agreement with Merck, a leading science and technology company, with the goal of advancing the development of novel Antibody-Drug Conjugates (ADCs) for cancer therapy.Read More
Ramot, TAU's Business Engagement Center Company, to launch i3 Equity Partners on campusRead More